• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1. Immunomodulating medicament of biological origin, of which the active principle is formed by the products of lysis or a fraction of these products of bacteria lysed by bacteriophagic route, characterised in that it contains, as active principle, the sterile lysis filtrate of at least two bacteria lysed by homologous bacteriophagic route ; the bacteria chosen being Klebsiella pneumoniae and Escherichia coli.
    公开号:SU1487815A3
    申请号:SU843781693
    申请日:1984-08-16
    公开日:1989-06-15
    发明作者:Iv-Mari Pazh；Kristin Vanderkhoven
    申请人:Lipha；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING A BIOLOGICALLY ACTIVE SUBSTANCE POSSESSING AN IMMUNITY SIMULATING. ACTION (57) The invention relates to medical microbiology and can be used to obtain immunomodulating drugs of microbiological origin. The purpose of the invention is to increase the activity of the target product. The method consists in separately cultivating strains of Exbb1CH1a coN of serovar 0119: B14 SISM No. 62.23 and K1eBb1e11a. Approximately 1 h after sowing, homologous bacteriophages are introduced into the culture fluids, the multiplicity of infection is 0.02-0.1. Cultivation is carried out to a residual concentration of 1000 bacterial cells / ml or less. The lysates are filtered and combined. The resulting preparation has a pronounced immunostimulating effect.
    s <o
    The invention relates to medical microbiology and can be used to obtain immunomodulating drugs of biological origin.
    The purpose of the invention is to increase the activity of the target product.
    Example p. For the preparation of the preparation, the strain Exciblacta cepa serovar 0119: B14 SLSM No. 62.23 and the strain K1ebc1e11a ppeisopen sysm No. 58.5 are used.
    Strain E. coH is grown in a nutrient medium containing 2.52 g / l of meat extract, 4.1 g / l of peptone, 7.0 g / l of sodium chloride and bidistilled water. The medium is inoculated with a bacterial inoculum, which is in the phase of exponential growth, the initial density of the culture is ΙχΙΟ ^ bacterial cells / ml. Incubation was carried out at 37 C under moderate stirring, about 60 minutes after sowing (exponential growth phase) bacteria infect a homologous phage relating to morphological C1 group. The multiplicity of infection is 0.02. Lysis is carried out using a cell counter, previously. calibrated. When less than'1000 bacteria / ml remains, the filtrate is sterilized by passing it through a filter membrane with a pore size of about 0.22 microns. Fil1487815 A5 waste from lysis itself is an immunomodulatory drug.
    The biological effect of лиз.οοίί lysate is enhanced by the addition of K. rpeitoptai lysate to it.
    To obtain the second component of the preparation, the strain K. rpeitopgee No. SDSM 58.5 is grown in a nutrient medium containing 3 g / l meat extract, g / l peptone, 7 g / l sodium chloride and bidistilled water.
    The medium is inoculated with a crop in the stationary growth phase. The initial density is 1 Ί 0 7 bacterial 15 cells / ml. The culture is grown at 37 ° C and mixed moderately.
    At the end of the latent phase (60 minutes after sowing), the culture is infected with a homologous phage of morphological group C1, the multiplicity of infection is 0.1.
    Lysis is performed using a cell counter. When less than 10 3 cells / ml remain, culture is stopped. The culture fluid is passed through the membrane of a sterilizing filter with a pore diameter of O, 22 μm. The lysate filtrate is mixed with the лиз.οοίί lysate filtrate to obtain a preparation of 30 mg having an immunomodulating effect.
    Examination of 15 people showed that oral administration of the drug entails a significant increase in immune responses 10 days 35 after administration.
    The resulting drug can be used for prevention and treatment. ny chronic respiratory infections 40 or their relapses. Two groups of 25 patients suffering from chronic bacterial infections or relapses at the bronchopulmonary level are orally administered with 15 ml of lysate 20 45 days per month for 3 months (experimental group), the other group is controlled with antibiotics. The decrease in the number of acute infectious diseases within 6 months (the duration of the experiment) was more significant in the experimental group than in the control group.
    This drug can also be used for postoperative infection prevention, for the prevention and treatment of urinary tract infections.
    • Unlike the well-known drug obtained by the prototype method, the obtained drug does not have a vaccinating property, but exhibits only the property of stimulating the body's immune defense. The drug induces the activity of serum interferon ίη νΐνο and ΐη νίϋΓο; active in stimulating the immune defense against infection by both the aforementioned and other types of bacteria.
    Thus, the use of the method allows to obtain a drug with a pronounced immunostimulating effect.
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining a biologically active substance having an immunostimulating effect by growing bacteria, followed by lysis of the obtained biomass and separation of the lysate from non-lysed bacteria, characterized in that, in order to increase the activity of the target product, bacteria use K1e3b1e11a peptopoera SDSM No. 58.5 and Ezbiebacterium spp. 11 0119: B14 SDSM No. 62.23, each strain is grown separately, biomass lysis is carried out to a residual concentration of 1000 bacterial cells / ml or less using homol tech bacteriophage at a multiplicity of infection of 0.02-0.1 and the resulting lysates were pooled.
    类似技术:
    公开号 | 公开日 | 专利标题
    Anwar et al.1990|Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa
    Vrabec et al.1965|LIX Scientific Papers of the American Otological Society: A Study of the Relative Concentrations of Antibiotics in the Blood, Spinal Fluid, and Perilymph in Animals
    Miller et al.1957|The effect of an antibiotic on the susceptibility of the mouse's intestinal tract to Salmonella infection
    SU1487815A3|1989-06-15|Method of producing biologically active substance having immunostimulating effect
    Isaacson et al.1988|Rothia dentocariosa endocarditis complicated by brain abscess
    KASAI et al.1984|In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic
    Smith et al.1976|The virulence of trimethoprim-resistant thymine-requiring strains of Salmonella
    US4472378A|1984-09-18|Live vaccine for the prevention of salmonellosis in water fowl, a process for making and applying the same
    RU2247775C1|2005-03-10|Liquid nutrient transporting medium for collection, culturing and transportation of patient blood with suspicion for brucellosis
    Satta et al.1988|Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections
    Bordley et al.1942|LXXXVI The Local use of the Sulfonamides, Gramicidin | and Penicillin in Otolaryngology
    EP2196533B1|2014-07-30|Novel microorganism having gastric juice promoting action and composition secreted by the same
    JP3002552B2|2000-01-24|Dermatitis treatment
    Karthigasu et al.1986|Vertebral osteomyelitis due to Staphylococcus warneri.
    US20020114794A1|2002-08-22|Staphylococcus aureus culture and preparation thereof
    CN108434438A|2018-08-24|Purposes and pharmaceutical composition of the antibacterial peptide in the drug for preparing treatment helicobacter pylori disease
    Glaser et al.1933|The culture of Paramecium caudatum free from living microorganisms
    Halbert et al.1950|In vivo antibiotic production by Escherichia coli
    RU2247148C2|2005-02-27|Strain of microorganism lactobacillus plantarum p4, strain of microorganism lactobacillus buchneri p0 and probiotic preparation based on thereof for correction of dysbacteriosis of different etiology in humans and animals
    SU1722502A1|1992-03-30|Medicinal preparation ъbiosporinъ for prevention and treatment of gastrointestinal diseases in man
    CS222673B2|1983-07-29|Method of making the immunobiotherapeutic means against infection disease of the breathing ways
    Wollstein1921|Studies on the phenomenon of d'Herelle with Bacillus dysenteriae
    SU1497211A1|1989-07-30|Strain of enterococcus streptococcus faecium used for preparing bacteritic preparations
    CN108653729B|2021-11-19|Vaginal foaming agent and application thereof
    RU2454238C1|2012-06-27|Biological preparation balis for preventing and treating infectious diseases
    同族专利:
    公开号 | 公开日
    CA1229566A|1987-11-24|
    ZA846151B|1985-03-27|
    DK393884D0|1984-08-16|
    HUT35013A|1985-05-28|
    EP0139551A3|1985-07-10|
    IN161616B|1988-01-02|
    IL72589A|1988-01-31|
    NO843274L|1985-02-18|
    OA07794A|1986-11-20|
    ES535213A0|1985-12-01|
    ES8602415A1|1985-12-01|
    AT36240T|1988-08-15|
    PT79090A|1984-09-01|
    FR2550707A1|1985-02-22|
    YU143284A|1991-02-28|
    AU3193884A|1985-02-21|
    NZ209171A|1988-10-28|
    HU193217B|1987-08-28|
    IL72589D0|1984-11-30|
    DK160807B|1991-04-22|
    PT79090B|1986-08-14|
    FR2550707B1|1986-02-28|
    AU564652B2|1987-08-20|
    CS270410B2|1990-06-13|
    DK393884A|1985-02-18|
    CS592184A2|1989-11-14|
    EP0139551B1|1988-08-10|
    DD232432A5|1986-01-29|
    DE3473228D1|1988-09-15|
    DK160807C|1991-10-07|
    MA20203A1|1985-04-01|
    JPS6069022A|1985-04-19|
    EP0139551A2|1985-05-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE758977A|1969-11-17|1971-05-17|Glaxo Lab Ltd|BIOCHEMICAL PROCESS|
    CH633188A5|1978-05-26|1982-11-30|Om Laboratoires Sa|MEDICINE FOR INFECTIOUS DISEASES OF THE RESPIRATORY TRACT.|
    CH639852A5|1979-07-26|1983-12-15|Om Laboratoires Sa|MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS.|
    US4322405A|1981-04-06|1982-03-30|Laboratoires Om Societe Anonyme|Method for treating rheumatoid arthritis|US4876194A|1986-07-22|1989-10-24|Hightech Receptor Ab|Protein L and subfragments thereof, with immunoglobulin binding activity, a process for preparing thereof, reagent kit, pharmaceutical composition and a peptococcus magnus strain|
    FR2620130B1|1987-09-08|1990-01-12|Lipha|NOVEL WATER-SOLUBLE POLYSACCHARIDES, PROCESS FOR OBTAINING THEM, USE THEREOF AS MEDICAMENTS AND PREPARATION CONTAINING THEM|
    IL88480D0|1987-11-27|1989-06-30|Univ Toronto|Proteinaceous compositions|
    AU6838996A|1996-05-27|1998-01-05|Alexei Nikolaevich Parfenov|Use of streptococcus faecium strains and composition containing the same|
    KR100965026B1|2002-02-13|2010-06-21|이뮤놀로지 래보러토리스 인코포레이티드|Compositions and methods for treatment of microbial infections|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR8313362A|FR2550707B1|1983-08-17|1983-08-17|IMMUNOMODULATOR OF BIOLOGICAL MEDICINE AND PROCESS FOR PREPARING THE SAME|
    [返回顶部]